SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

AST Spacemobile, Inc. engages in building a broadband cellular network in space to operate directly with standard, unmodified mobile devices based on an extensive IP and patent portfolio. It focuses on providing mobile broadband services with global coverage to all end-users, without the need to purchase special equipment. The company was founded by Abel Avellan on May 31, 2017 and is headquartered in Midland, TX.

AST SpaceMobile Inc - Ordinary Shares - Class A

AST SpaceMobile Inc

AST SpaceMobile is trending after successfully unfolding its BlueBird 6 satellite, the largest commercial communications array ever deployed in low Earth orbit, and securing recent FCC approval for U.S. testing with major carriers, sparking community discussions about potential short squeezes and accelerated commercial rollout.

Robinhood Markets, Inc is a financial services platform, which engages in the provision of retail brokerage and offers trading in U.S. listed stocks and Exchange Traded Funds, related options, and cryptocurrency trading, as well as cash management, which includes debit cards services. The company was founded by Vladimir Tenev and Baiju Prafulkumar Bhatt in 2013 and is headquartered in Menlo Park, CA.

Robinhood Markets Inc - Ordinary Shares - Class A

Robinhood Markets Inc

Robinhood is trending following its Q4 2025 earnings report, which revealed a revenue miss largely attributed to a decline in crypto trading, while still beating EPS expectations and showcasing growth in other areas. The community is sharply divided, with some investors seeing the dip as a prime buying opportunity due to diversification into new products like prediction markets and a strong long-term vision, while others warn of overvaluation and continued vulnerability to crypto market performance.

Mattel, Inc. engages in the ownership of children's and family entertainment franchises. It operates through the following segments: North America, International, and American Girl. The North America and International segments focus on marketing and selling toys and consumer products. The American Girl segment includes marketing, retailing, and publishing dedicated to its mission to help girls grow up with confidence and character. The company was founded by Elliot Handler, Ruth Handler, and Harold Matson in 1945 and is headquartered in El Segundo, CA.

Mattel, Inc.

Mattel is trending following a significant Q4 earnings miss and a cautious FY26 outlook, triggering a sharp decline that saw the stock plummet from a 52-week high to near a 52-week low in a single trading session. The community is actively debating whether the sell-off is an overreaction, presenting a buying opportunity, or if it reflects deeper concerns for the toy sector.

Ford Motor Co. engages in the manufacture, distribution, and sale of automobiles. It operates through the following segments: Ford Blue, Ford Model E, Ford Pro, Ford Next, Ford Credit, and Corporate Other. The Ford Blue, Ford Model E, and Ford Pro segment includes the sale of Ford and Lincoln vehicles, service parts, and accessories, together with the associated costs to develop, manufacture, distribute, and service the vehicles, parts, and accessories. The Ford Next segment is involved in the expenses and investments for emerging business initiatives aimed at creating value for Ford in vehicle-adjacent market segments. The Ford Credit segment consists of the Ford Credit business on a consolidated basis, which is primarily vehicle-related financing and leasing activities. The Corporate Other segment refers to corporate governance expenses, past service pension and OPEB income and expense, interest income and gains and losses from cash, cash equivalents, and marketable securities, and foreign exchange derivatives gains, and losses associated with intercompany lending. The company was founded by Henry Ford on June 16, 1903 and is headquartered in Dearborn, MI.

Ford Motor Co.

Ford Motor Co

Ford is trending following a significant Q4 net loss largely due to EV restructuring, yet optimistic 2026 adjusted EBIT guidance and a recent analyst upgrade are driving positive sentiment. The community is actively discussing the company's long-term strategy amidst mixed signals from EV challenges, strong hybrid sales, and new U.S. vehicle loan tax incentives.

Lyft, Inc. engages in the provision and management of an online social rideshare community platform. It offers access to a network of shared bikes and scooters for shorter rides and first mile and last-mile legs of multimodal trips, information about nearby public transit routes, and Lyft Rentals to offer riders a view of transportation options when planning any trip. The company was founded by Marcus Cohn, John Zimmer, Rajat Suri, Matt van Horn, and Logan Green in 2007 and is headquartered in San Francisco, CA.

Lyft Inc - Ordinary Shares Cls A

Lyft Inc

Lyft is experiencing significant volatility following mixed earnings, which showed strong rider growth and a substantial share buyback despite some revenue concerns. The community is sharply divided, with bulls highlighting the company's valuation, CEO confidence, and future in autonomous vehicles and European expansion, while bears focus on competitive pressures, the one-time EPS beat, and the long-term threat of robotaxis.

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. It operates through the following geographical segments: United States, Europe, and Rest of World. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rossi, and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Moderna Inc

Moderna is trending due to an immediate regulatory setback, as the FDA refused to review its influenza vaccine application over trial design concerns, which has ignited strong community debate and criticism towards the agency. This contrasts with recent optimism from promising five-year data for its personalized cancer vaccine, fueling a divided outlook on the mRNA platform's future beyond infectious diseases amid ongoing patent litigation.

Shopify, Inc. is a global commerce company that provides essential internet infrastructure for commerce, offering trusted tools to start, scale, market, and run a retail business of any size. The Company's software enables merchants to run their business across all of their sales channels, including web and mobile storefronts, physical retail locations, social media storefronts and marketplaces. The Shopify platform provides merchants with a single view of their business across all of their sales channels and enables them to manage products and inventory, process orders and payments, fulfill and ship orders, build customer relationships, source products, leverage analytics and reporting and access financing, all from one integrated back office. The company was founded on September 28, 2004 and is headquartered in Ottawa, Canada.

Shopify Inc - Ordinary Shares - Class A (Sub Voting)

Shopify Inc

Shopify is experiencing intense trading volatility ahead of its earnings report, fueling a community debate over whether its recent sharp dip represents a prime buying opportunity or signals further downside. Investors are closely watching for updates on AI integration and e-commerce growth, amidst broader market speculation about AI's impact on the software sector.

Upstart Holdings, Inc. engages in the provision of a cloud-based artificial intelligence lending platform. It operates through the following segments: Personal Lending, Auto Lending, and Other. The Personal Lending segment focuses on unsecured personal loans and small dollar loans. The Auto Lending segment is involved in auto refinance and auto retail loans. The Other segment refers to HELOCs and other. The company was founded by David Joseph Girouard, Anna Mongayt Counselman, and Paul Gu in December 2013 and is headquartered in San Mateo, CA.

Upstart Holdings Inc

Upstart Holdings is trending following an earnings report showcasing revenue and EPS beats, robust loan origination growth, and a leadership transition, fueling a divided investor debate. Bulls foresee continued upside driven by its AI lending model and potential for a short squeeze, contrasting with bears who remain wary of broader macroeconomic credit risks despite the strong performance.

Evommune, Inc. is a clinical-stage biotechnology company. It engages in the development of medicines for inflammatory diseases. The company was founded by Luis C. Pena, Eugene Andrew Bauer, and Hans Hofland in 2020 and is headquartered in Palo Alto, CA.

Evommune Inc.

Evommune Inc

Evommune Inc. is trending significantly higher following positive top-line data from its Phase 2a trial for EVO301 in moderate-to-severe atopic dermatitis, which met its primary endpoint with statistically significant outcomes. The community is actively debating its strong momentum, with many anticipating further upside and analysts raising price targets, while some traders consider profit-taking amid the rally.

QuickLogic Corp. operates as a semiconductor company, which designs, markets, and supports primarily Customer Specific Standard Products and secondarily, Field Programmable Gate Arrays, sensor software algorithms, software drivers, associated design software and programming hardware. It develops and markets low power customizable semiconductor and software algorithm solutions that enable customers to differentiate their products by adding new features, extending battery life, becoming more contextually aware and improving the visual experience with their mobile, consumer and enterprise products. The company was founded by John M. Birkner, Andrew K. Chan, and Hua-Thye Chua in 1988 and is headquartered in San Jose, CA.

Quicklogic Corp

Quicklogic Corp is trending due to renewed optimism surrounding its critical role in national security and domestic chip production, driven by the recently funded FY2026 defense budget accelerating awards for its unique radiation-hardened FPGA technology. The community is buzzing about its position as the sole trusted onshore eFPGA provider for Intel's advanced 18A node and its growing chiplet initiatives, anticipating significant future revenue.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Given Consensus Rating of "Moderate Buy" by Analysts

Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Get Free Report) has been assigned a consensus rating of "Moderate Buy" from the twelve analysts that are currently covering the stock, Marketbeat...

Lisanti Capital Growth LLC Purchases New Position in Crinetics Pharmaceuticals, Inc. $CRNX

Lisanti Capital Growth LLC purchased a new stake in shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) in the 3rd quarter, according to the company in its most recent 13F filing...

Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Given Average Recommendation of "Moderate Buy" by Analysts

Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Get Free Report) have earned an average rating of "Moderate Buy" from the fourteen brokerages that are currently covering the firm, MarketBeat...

The Goldman Sachs Group Upgrades Crinetics Pharmaceuticals (NASDAQ:CRNX) to Buy

The Goldman Sachs Group upgraded shares of Crinetics Pharmaceuticals from a "neutral" rating to a "buy" rating and set a $67.00 price objective on the stock in a research report on Monday...

Crinetics Pharmaceuticals (NASDAQ:CRNX) Stock Price Down 8.2% - Here's What Happened

Crinetics Pharmaceuticals (NASDAQ:CRNX) Stock Price Down 8.2% - Here's Why...

Morgan Stanley Increases Crinetics Pharmaceuticals (NASDAQ:CRNX) Price Target to $80.00

Morgan Stanley upped their price target on shares of Crinetics Pharmaceuticals from $77.00 to $80.00 and gave the company an "overweight" rating in a report on Tuesday...

<ul class="summary-bullets"><li>The trial was aimed at evaluating the efficacy, safety, and pharmacokinetics of Atumelnant when administered for 12 weeks in people with congenital adrenal hyperplasia caused by 21-hydroxylase deficiency.</li><li>Following the announcement, Evercore ISI raised the firm's price target on Crinetics to $90 from $80 and keeps an Outperform rating on the shares following what the firm views as "very strong updates."</li><li>Crinetics also reported unaudited and preliminary net product revenue of over $5 million in fourth-quarter 2025 for its new drug Palsonify in the U.S.</li></ul><p>Crinetics Pharmaceuticals, Inc. (CRNX) said on Monday that its experimental drug Atumelnant yielded positive results in the fourth cohort of a congenital adrenal hyperplasia trial (CAH), sending shares up 3% in Monday’s mid-day trading. &nbsp;</p><p>Atumelnant is a once-daily oral adrenocorticotropic hormone (ACTH) receptor antagonist candidate being developed for the treatment of classic congenital adrenal hyperplasia as well as adrenocorticotropic hormone-dependent Cushing’s syndrome.</p><p>The company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2026/01/05/3212693/0/en/Crinetics-Announces-Strong-PALSONIFY-Launch-Execution-and-Positive-Results-for-Concurrent-Androstenedione-Lowering-and-Glucocorticoid-Dose-Reduction-in-Phase-2-Trial-of-Atumelnant-.html?_gl=1*dclqt*_up*MQ..*_ga*MTQ5MTU3MjU2MS4xNzY3NjMzMDE2*_ga_ERWPGTJ5X8*czE3Njc2MzMwMTUkbzEkZzAkdDE3Njc2MzMwMjIkajUzJGwwJGgw">said</a> that treatment with Atumelnant resulted in rapid, sustained lowering of androstenedione in all eight patients that completed the fourth cohort of the mid-stage trial.</p><p>Shares of Neurocrine Biosciences (NBIX), whose Crenessity drug is approved for CAH, fell by 3% following the rival’s update.</p><h2 class="st-heading-2">Trial Results</h2><p>The trial was aimed at evaluating the efficacy, safety, and pharmacokinetics of Atumelnant when administered for 12 weeks in people with CAH caused by 21-hydroxylase deficiency. CAH is a group of genetic disorders affecting the adrenal glands, preventing them from producing enough cortisol and aldosterone. It leads to issues with energy, blood sugar, blood pressure, salt/water balance, and sexual development.</p><p>The drug was observed to be well-tolerated, with no serious adverse events and no treatment-related severe adverse events, the company added.</p><h2 class="st-heading-2">Positive Feedback For Palsonify</h2><p>Separately, Crinetics also reported unaudited and preliminary net product revenue of over $5 million in fourth-quarter 2025 for its new drug Palsonify in the U.S.</p><p>Palsonify was approved by the U.S. Food and Drug Administration (FDA) on September 25 for the first-line treatment of adults with acromegaly who had an inadequate response to surgery and/or for whom surgery is not an option.</p><p>The company noted that feedback from patients, physicians and payers have been positive thus far.</p><h2 class="st-heading-2">Expert Take</h2><p>Following the announcement, Evercore ISI raised the firm's price target on Crinetics to $90 from $80 and keeps an Outperform rating on the shares following what the firm views as "very strong updates," as per TheFly.</p><p>The firm believes the Atumelnant update will be "much more impactful" for the stock today as it contends that Crinetics "again looks to comfortably have 2 blockbuster," high odds of success products and more in earlier development.</p><p>RBC Capital analyst Brian Abrahams noted that the data looked very supportive of the drug's ability to be a potential competitor that could reach the CAH market within the next few years, according to TheFly. However, the firm believes comparing the dataset to Neurocrine's phase III study data is limited, primarily due to the differences in patient population. Overall, RBC notes that while competitor data reaffirms a potential emerging player in the CAH space, this was already well known, patient stickiness may shield Crenessity from future competition. Even with conservative estimates, it sees Crenessity contributing $1.1 billion to Neurocrine's revenue stream in the U.S. market alone.</p><p>RBC added that it would be a buyer of Outperform-rated Neurocrine on weakness.</p><h2 class="st-heading-2">How Did Stocktwits Users React?</h2><p>On Stocktwits, retail sentiment around CRNX stock jumped from ‘bearish’ to ‘bullish’ territory over the past 24 hours, while message volume rose from ‘normal’ to ‘extremely high’ levels at the time of writing. Sentiment around <a href="https://stocktwits.com/symbol/NBIX">NBIX stock</a> stayed within the ‘bearish’ territory in the same time.</p><p><a href="https://stocktwits.com/symbol/CRNX">CRNX stock</a> has dropped 5% over the past 12 months.&nbsp;</p><p>Read also: <a href="https://stocktwits.com/news-articles/markets/equity/general-motors-q4-deliveries-dive-on-lower-ev-sales/cmxMtAZR4RJ">General Motors Q4 Deliveries Dive On Lower EV Sales — Automaker Looks To Next-Generation Bolt EV For Bounceback</a></p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p>

 In this photo illustration, the Crinetics Pharmaceuticals logo is seen displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

CRNX Stock Gains, NBIX Shares Drop On Positive Results From Genetics Disorder Trial

Crinetics Pharmaceuticals said that treatment with experimental drug Atumelnant resulted in rapid, sustained lowering of androstenedione in eight patients that completed the fourth cohort of a congenital adrenal hyperplasia trial.

Equity

Crinetics Pharmaceuticals said that treatment with experimental drug Atumelnant resulted in rapid, sustained lowering of androstenedione in eight patients that completed the fourth cohort of a congenital adrenal hyperplasia trial.


Crinetics Pharmaceuticals (NASDAQ:CRNX) Hits New 52-Week High - Still a Buy?

Crinetics Pharmaceuticals (NASDAQ:CRNX) Reaches New 52-Week High - Should You Buy...

Crinetics Pharmaceuticals touts $5M Palsonify Q4 launch, posts strong atumelnant phase 2 CAH data

Crinetics Pharmaceuticals (NASDAQ:CRNX) provided a corporate update highlighting early commercial progress for Palsonify in acromegaly and new phase 2 data for atumelnant in congenital adrenal...

Crinetics Pharmaceuticals (NASDAQ:CRNX) Upgraded at Wall Street Zen

Wall Street Zen raised Crinetics Pharmaceuticals from a "sell" rating to a "hold" rating in a research note on Saturday...

Crinetics Pharmaceuticals, Inc. operates as a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its product candidate, CRN00808, is an oral nonpeptide somatostatin agonist for the treatment of acromegaly. The firm is also developing other oral nonpeptide somatostatin agonists for neuroendocrine tumors and hyperinsulinism, as well as an oral nonpeptide ACTH antagonist for the treatment of Cushing's disease. The company was founded by R. Scott Struthers, Yun-Fei Zhu and Stephen F. Betz in 2008 and is headquartered in San Diego, CA.

Crinetics Pharmaceuticals Inc

Beat EPS and revenue

Beat EPS, miss revenue

Miss EPS, beat revenue

Miss EPS and revenue

What do you expect from $SHOP earnings on Wednesday?

CRNX
Crinetics Pharmaceuticals Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest CRNX News

CRNXCrinetics Pharmaceuticals Inc